Inclusion Criteria:

- Adult patients >/= 18 years of age

- Newly diagnosed, histologically confirmed glioblastoma not previously treated with
chemotherapy or radiotherapy

- Female patients of childbearing potential and fertile male patients must agree to use
effective contraception as defined by protocol for the duration of the study and for
at least 6 months following the last administration of study drugs

- Karnofsky performance status (KPS) >/= 60

Exclusion Criteria:

- Any prior chemotherapy for glioblastoma and low grade astrocytomas

- Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential
overlap in the radiation field

- Prior or current anti-angiogenic treatment

- Treatment with any other investigational drug within 28 days or 2 investigational
agent half-lives (whichever is longer) prior to first study treatment

- Inadequate hematological, renal or liver function

- Inadequately controlled hypertension

- Prior history of gastrointestinal perforation or abscess

- Clinically significant cardiovascular disease, NYHA >/= Grade II congestive heart
failure, or serious cardiac arrhythmia uncontrolled by medication or potentially
interfering with protocol treatment

- History or evidence of central nervous system disease unrelated to cancer unless
adequately treated with standard medical therapy

- History or evidence of inherited bleeding diathesis or significant coagulopathy at
risk of bleeding

- Serious non-healing wound, active ulcer, or untreated bone fracture

- Known hypersensitivity to any component of Avastin/placebo or any of the study drugs

- Active infection requiring intravenous antibiotics at start of study treatment

- Other malignancy within 5 years prior to study enrolment, except for carcinoma in
situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or
ductal carcinoma in situ treated with curative intent

- Pregnant or lactating women